

Date and Time: *Tuesday 9 May 2017, 10:00-16:00*

Minutes: Confirmed

**Asthma Diagnosis & Monitoring Guideline Committee (GC)
Meeting 15**

Place: *Laurie Landeau, 41 Portland Place, London W1B 1QH*

Present:	John Alexander (JA)	Consultant in Paediatrics & Paediatric Intensive Care, University Hospitals of North Midlands NHS Trust
	Erol Gaillard (EG)	Senior Lecturer & Honorary Consultant in Paediatric Respiratory Medicine, University Hospitals of Leicester NHS Trust
	Val Hudson (VH)	Lay member
	Matthew Masoli (MM)	Consultant Respiratory Physician, Plymouth Hospitals NHS Trust
	Melanie McFeeters (MMF)	Quality Lead for Specialised Commissioning, NHS England
	Andrew Menzies-Gow	Committee Chair, Consultant Respiratory Physician, Royal Brompton & Harefield NHS Foundation Trust
	Tahmina Siddiqui (TS)	General Practitioner, Whaddon Medical Centre, Milton Keynes
	Michael Thomas (MT)	Professor of Primary Care Research, University of Southampton
	Alex Haines (AH)	Senior Health Economist, NGC
	Bernard Higgins (BH)	Clinical Director & Guideline Lead, NGC
	Kate Kelley (KK)	Operations Director, NGC (items 3-4 only)
	Amelia Unsworth (AU)	Senior Project Manager, NGC (notes)
	Caroline Keir (CK)	Guidelines Commissioning Manager, NICE
	Heather Stephens (HS)	Senior Medical Technology Implementation Manager, NICE (items 1-3 only)
	Adam Storrow (AS)	Resource Impact Analyst, NICE (items 1-5 only)

Apologies:

Catharine Baden-Daintree (CBD) Senior Medical Editor, NICE

Notes

1. The Chair welcomed the group to the fifteenth meeting of this GC. Introductions were made. Apologies were received from CBD.

2. The Chair reviewed and requested updates to the declarations of interest register. The following new declarations of interest were received for this GC meeting:

GC Declarations of Interest			
N.B. The Chair and GC members were recruited to this guideline using NICE DOI policy published April 2007.			
Insert initials	Declaration	Classification (as per the NICE DOI policy wording*)	Chair's action
AMG	<p>In the last 12 months:</p> <p>I have attended advisory boards and or received lecture fees from: Astra Zeneca, Glaxo SmithKline, Teva, Napp, Mundi Pharma, Novartis, Boehringer Ingelheim, Vectura and Hoffman La Roche.</p> <p>I have attended international conferences with Napp and Boehringer Ingelheim.</p> <p>I have participated in clinical studies for which my institution has been reimbursed with Glaxo SmithKline, Hoffman La Roche and Boehringer Ingelheim.</p> <p>I have consultancy agreements with Astra Zeneca and Vectura.</p>	Personal financial non-specific	Declare and participate (2007 DOI policy)
EG	<p>Received grants and consultancy paid to his institution from Vertex and Boehringer Ingelheim.</p> <p>Has research grants from Astra Zeneca and Circassia.</p>	Specific non-personal pecuniary	Declare and withdraw for FeNO and the HE model but can answer questions on request by the Chair.
NICE DOI policy classifications are:			

- Personal financial specific
- Personal financial non-specific
- Personal non-financial specific
- Personal non-financial non-specific
- Non-personal financial specific

It was noted that MT's previously declared COI relating to Aerocrine (now Circassia) has expired; therefore MT can participate in discussions on FeNO and the HE model.

3. The GC was given a presentation on the results of the NICE feasibility project.
4. The GC was given a presentation on the surveillance review.
5. The GC discussed and agreed changes to the diagnostic algorithms.
6. The GC discussed the points raised by PCRS-UK in its letter to NICE dated 28 February 2017.
7. AOB: there was no other business.

Date of next meeting: GC16: Tuesday 15 August 2017, 10:00-16:00, WebEx meeting.